Clinical trial
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity
NCT04099667 is registered in ClinicalTrials.gov with Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity
- Lead sponsor
- Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
- Phase
- Phase 2/3
- Overall status
- Terminated
- Start date
- December 17, 2019
- Completion date
- March 24, 2023
- Enrollment
- 40 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
spasticity